The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C03 | Diuretics | |
3
|
C03D | Potassium-sparing agents | |
4
|
C03DA | Aldosterone antagonists | |
5
|
C03DA01 | Spironolactone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 75 mg |
| Active Ingredient |
|---|
|
Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action. |
| Document | Type | Information Source | |
|---|---|---|---|
| ALDACTONE Film-coated tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| QAIALDO Oral suspension | MPI, EU: SmPC | European Medicines Agency (EU) | |
| SPIRACTIN Tablet | MPI, EU: SmPC | Marketing Authorisation Holder | |
| SPIROLON Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| URACTONUM Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.